Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

by | PRNewswire Asia

Collaboration will evaluate Akeso’s cadonilimab in combination with INOVIO’s INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancer Novel combination therapy will be studied as...

Colgate Partners with Hong Kong Dental Association and Mannings to Launch Hong Kong's First TOTAL Periodontal Health Lab at Olympian City

by | PRNewswire Asia

Interactive Pop-up Offers Professional Screenings, Expert Consultations, and Exclusive Rewards to Promote Proactive Gum Care and Holistic Public Health HONG KONG, March 4, 2026 /PRNewswire/ — Recognizing that gum health is the foundation of systemic...

HKSH Medical Group Collaborates with China Life (Overseas) Providing High-End Clients with Bespoke, One-Stop Healthcare and Concierge Services

by | PRNewswire Asia

HONG KONG, March 4, 2026 /PRNewswire/ — HKSH Medical Group (HKSH) and China Life Insurance (Overseas) Company Limited (CLIO) formed a strategic collaboration, with HKSH becoming the first healthcare institution in Hong Kong to offer personalised, end-to-end...

SLEEP WELL, LIVE BETTER: WESTIN HOTELS & RESORTS PUTS REST AT THE HEART OF TRAVEL THIS WORLD SLEEP DAY 2026

by | PRNewswire Asia

From Sleep Expert Sessions to Sound Baths Under the Stars, Westin Hotels & Resorts Across the Region Showcase Comprehensive ‘Sleep Well’ Programs Through Culturally Immersive Experiences SINGAPORE, March 4, 2026 /PRNewswire/ — As World Sleep Day...

PROTECTHEALTH STRENGTHENS GOVERNANCE AND SERVICE CONTINUITY WITH ISO 22301 BCMS CERTIFICATION

by | PRNewswire Asia

CYBERJAYA, Malaysia, March 4, 2026 /PRNewswire/ — ProtectHealth Corporation Sdn. Bhd. has reinforced its role as a key government agency and strategic purchaser of healthcare services with the successful attainment of the ISO 22301:2019/AMD1:2024 Business...

Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases

by | PRNewswire Asia

Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases. Antengene will receive USD 80 million of upfront and near-term...